Wyeth's Xyntha gets FDA OK

02/21/2008 | MarketWatch

The FDA on Thursday announced that it has cleared Wyeth's drug Xyntha as treatment for rare blood-clotting disorder hemophilia A. The drug is indicated for regulating and preventing spontaneous or post-injury bleeding in patients with the disorder.

View Full Article in:

MarketWatch

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA